Kornimate/medical-research-clean huggingface dataset:
the e-bild study: effects of e-cigarettes on lung health in teenagers.

Conditions: Vaping; Lung Diseases

Summary: electronic nicotine delivery systems (ends/e-cigarettes/vaping) are increasingly popular among teenagers around the world. the safety and potential adverse effects of ends in this population are largely unknown. while the aerosol, that users inhale, appears safe under laboratory conditions, there are still open questions, which have not yet been assessed. these cover (a) differences in exposure to chemicals (such as metabolites of volatile organic compounds (vocs) and metabolites of polycyclic aromatic hydrocarbons (pahs)) between healthy teenagers using ends and healthy teenagers not vaping, (b) effects of exposure to such chemicals on the body (measured by lung health indicators: airway symptoms such as coughing; lung function and lung structure tests; immune response of airway cells exposed to vapor; markers of oxidative stress), and (c) the role of nicotine metabolism. it is unknown which lung health indicator/s is/are most relevant to assess the effect of ends on lung health in teenagers. the primary hypothesis of this study is that there will be differences in exposure to chemicals, resulting in more or more severe airway symptoms in vaping teenagers compared to their non-vaping peers. while there might not yet exist any differences regarding lung function or structure, we expect already visible effects of vaping on the local immune response of primary cells isolated from airways in vaping teenagers as compared to non-vaping peers. in this study, participants of the bern basel infant lung development (bild) cohort, a birth cohort of healthy term-born infants and their follow-up, will serve as healthy, non-vaping controls.1 vaping teenagers will be recruited independently from the bild study through advertisements and visits to bernese schools. both populations combined represent the study population of the e-bild study. all e-bild study participants will undergo the same investigations. while these are currently planned for once in a time (so-called cross-sectional design) to compare results from non-vaping bild study participants to otherwise healthy but vaping teenagers, repeated measures might follow, depending on the findings of the first phase.


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * bild study participants: see inclusion criteria of bild study (nct04286464), non-vaping * e-bild: healthy, term-born, vaping at least weekly (might include healthy, vaping participants from bild) exclusion criteria: • none, except for general exclusion criteria of bild study (nct04286464)
low-dose aza combined with short term cag derived regimen as a bridging treatment in patients with advanced mds prior to allo-hsct

Conditions: MDS-EB

Summary: this single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (aza) in combination with short term cag derived regimen prior to allogeneic stem cell transplantation (allo-hsct) in patients with advanced myelodysplastic syndromes (mds) .


Eligibility criteria:
inclusion criteria: * new diagnosed advanced myelodysplastic syndrome (mds) for whom an allogeneic hematopoietic stem cell transplant is planned * recipient of an allogeneic hematopoietic stem cell transplantation * age \< 65 years * ecog performance status ≤2 * written informed consent * no psychological, familial, social, or geographic reason that would compromise clinical follow up exclusion criteria: * relapsed or refractory advanced mds * severe pshyciatric or organic disorder, supposed to be independent from advanced mds, that would contraindicate treatment * known allergic or hypersensitivity to azacitidine, aclarubicin or cytarabine or to any of the test compounds, materials * concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place the subject at unacceptable risk * a co-morbid condition which, in the view of the investigators, renders the subject at high risk from treatment complications
integrated care pathway for youth depression

Conditions: ICP1; Depression; Adolescent Behavior

Summary: major depressive disorder in adolescence is prevalent and debilitating. our group aims to improve treatment response through the use of an integrated care pathway (icp) based on a high quality clinical practice guideline and measurement-based care (mbc; where periodic symptom scale scores are used to make treatment decisions). we propose a controlled clinical trial comparing icp to treatment-as-usual (tau) across two sites.

background: there is a gap between what is known from the evidence about the treatment of adolescent depression and what is practiced. moreover, while there is evidence that measurement-based care can improve outcomes for adults with various mental health conditions, there is limited information on this framework in adolescent depression. objective: our study aims to enhance the implementation of evidence-based care (using the nice clinical practice guidelines as a template) combined wtih measurement-based care through the use of an integrated care pathway (icp) in adolescents with depression. hypothesis: as this is a pilot study, our hypotheses centre around feasibility. we hypothesize that: (1) we will recruit at least 30 participants to the icp treatment arm and 30 participants at the "treatment-as-usual" arm at a different site (2) that baseline measures will be fully completed by 95% of adolescents recruited, (3) that baseline measures will take 2 hours to complete for adolescents and 1 hour to complete for caregivers, (4) that a mean of 90% of the key aspects of the treatment protocol are followed in the icp group (5) that 80% of participants recruited will complete measures at the end of the 20-week interval and that (6) 90% of the youth, caregivers and clinicians who partake int eh study will attend a focus group to provide qualitative feedback on their experience. design: this is a non-randomized controlled clinical trial. randomizing at the individual level is not possible - the intervention is implemented at the clinic level; so the effect of the intervention on one youth within a clinic would influence the care of other youth at the clinic. sampling: participants are recruited from psychiatric clinics at 2 sites. each site will recruit to their respective treatment arm.

Eligibility criteria:
inclusion criteria: * psychiatrist's impression is that depression is a primary psychiatric. concern * 14-18 years old. * dsm-5 criteria for major depressive disorder or persistent depressive disorder as per the diagnostic interview for affective symptoms for children (dias-c19). * speak, read and write english at a grade 6 level. exclusion criteria: * threshold psychotic symptoms. * bipolar disorder. * moderate-to-severe substance use disorder. * autistic spectrum disorder or intellectual disability. * eating disorder. * suicide-related behaviours requiring acute intervention.
an open-labeled, extended-use of xerecept (hcrf) for patients in studies nti 0302, 0303, or other designated studies

Conditions: Brain Edema; Brain Tumor

Summary: the purpose of this study is to examine the long-term safety and tolerability of human corticotropin-releasing factor (hcrf), xerecept®, in patients requiring dexamethasone (decadron) to treat peritumoral brain edema. this open-label, extended-use study is open to all patients who participate in either of the blinded studies, nti 0302, nti 0303, or other designated studies, including patients who may have discontinued blinded study medication early but completed the protocol-stipulated follow-up periods.

xerecept® is not a potential treatment for cancer, but may reduce the edema associated with tumors and as a result, decrease neurological symptoms.

Eligibility criteria:
inclusion criteria: * participation in and completion of stipulated final follow-up periods for study nti 0302, nti 0303, or other designated studies. * have a karnofsky performance of \> 50 at baseline * capable of self-administration of subcutaneous injections twice daily or availability of assistance from caregiver. * ability to provide written informed consent or, if unable to provide, have a legal guardian or representative provide written informed consent. * for women of childbearing potential: a negative serum pregnancy test at baseline exclusion criteria: * concurrent enrollment in any investigational drug or device study, other than nti 0302, nti 0303, or other designated studies. * systemic steroid use for any indication other than peritumoral brain edema. * use or intended use of dexamethasone as an anti-emetic during study. * clinical signs and symptoms of cerebral herniation. * serious concomitant cardiovascular, pulmonary, renal, gastrointestinal or endocrine metabolic disease which could put the patient at unusual risk during study participation. * confounding previous or concurrent neurological disorders that would interfere with adequate clinical evaluation. * clinically significant head injury or chronic seizure disorder, if the condition results in functional impairment or is likely to interfere with evaluations.(maintenance anticonvulsant therapy is allowed) * central nervous system (cns) infection. * pregnancy, breastfeeding and/or refusal to practice birth control while in study, for women of childbearing potential.

Keywords: peritumoral brain edema edema malignant brain tumor astrocytoma brain tumor dexamethasone decadron
patient outcomes collection: how can we do better?

Conditions: Shoulder Pain

Summary: patient reported outcomes (pros) are widely used by clinical providers as important tools to help inform their clinical and research practice, and to improve quality of care for patients. in this study, the investigators aim to investigate ways by which patient pro completion rates may be improved.

patient reported outcomes (pros) are widely used by clinical providers as important tools to help inform their clinical and research practice, and to improve quality of care for patients. in addition, pros are increasingly cited as a tool in measuring surgical performance and the value of health care services being delivered. the quality of data captured by pros is, however, largely dependent on patients' response rates, both pre- and post-operatively. for pre-operative surveys, higher response rates may be achieved as patients may be reminded to complete their surveys at an office visit or prior to surgery. however, patient non-compliance presents a major challenge post-operatively, undermining pro data integrity. as clinical practices have moved to using pros for all patients, rather than just a research tool, automated systems have been developed to deliver and collect pro electronically. however, while automation has helped streamline pro administration and data collection, this hasn't always translated into obtaining better pro compliance rates. in an attempt to improve response rates, efforts have been made to reduce patient burden (by reducing the number of questions asked, for example), to regularly remind patients to complete their forms (either by email or telephone), or even offer patients monetary or non-monetary incentives. despite these measures' variable success, however, achieving high response rates remains a challenge. this, in part, is due to the fact these platforms depend heavily on patients receiving the request and their willingness to participate in the program, often long after their care is completed. as data are increasingly used to measure physician performance and quality, as well as to determine reimbursement, low patient compliance rates remain a significant impediment and affect the validity of the data. in this study, the invetigators hypothesize that direct patient engagement can improve patient compliance with automated pro capture.

Eligibility criteria:
inclusion criteria: * patients scheduled to undergo shoulder arthroscopy for rotator cuff condition (sub-acromial decompression, distal clavicle resection, biceps tenodesis, partial or full thickness rotator cuff tear repair or debridement) will be eligible for enrollment in the appropriate cohort. there will be no restrictions to this enrollment apart from that presented in the exclusions below. exclusion criteria: 1. minors or those over the age of 80 2. subjects lacking english proficiency to complete the pros of interest. 3. past or current medical history that would preclude patients from undergoing surgery.

Keywords: shoulder arthroscopy sub-acromial decompression distal clavicle resection biceps tenodesis rotator cuff repair patient reported outcomes
role of cxcr2 ligands/cxcr2 biological axis in pancreatic cancer

Conditions: Chronic Pancreatitis; Pancreatic Cancer

Summary: the investigators hypothesize that the cxcr2 ligands/cxcr2 biological axis plays an important role in promoting angiogenesis in pc; and that the genetic changes and the microenvironment of the tumor regulate the expression of cxcr2 ligands/cxcr2 in pc in order to potentiate their angiogenic phenotype. a corollary of this hypothesis is that the cell surface receptors (cxcr2) and the intracellular signaling pathways that mediate the angiogenic responses induced by elr+ cxc-chemokines are potential targets for novel therapeutic interventions in pc.


Eligibility criteria:
inclusion criteria: * normal subjects - no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test. (eus, ct scan or mri) * chronic pancreatitis - documented diagnosis of moderate to advanced chronic supported bpancreatitisy at least 1 positive imaging test. (eus, ct scan or mri) * pancreatic cancer - documented tissue diagnosis (or clinical suspicion) of pancreatic cancer. exclusion criteria: * exclusion criteria will include age younger than 18 yrs, pregnancy, previous pancreatic or gastric resection, and inability to tolerate routine endoscopy with conscious sedation
polish survey on the efficacy of the hypercholesterolemia treatment

Conditions: Hypercholesterolemia

Summary: the purpose of the survey is to evaluate the efficacy of treatment of hypercholesterolemia in polish patients who are currently on lipid- lowering pharmacological therapy . efficient treatment is defined as achievement of the ldl cholesterol level goals according to the european society of cardiology 2007 guidlines.


Eligibility criteria:
inclusion criteria: * patients on lipid lowering drug treatment * lipid lowering drug treatment lasting at least 3 months * no lipid lowering drug/dose change for a minimum 6 weeks prior to enrolment to the study exclusion criteria: * lack of patient's signed informed consent form * lack of the blood sample taken for lipid profile and glucose within 10 days before or after assessment of the patient

Keywords: hypercholesterolemia low density lipoprotein undertreatment of hypercholesterolemia
promoting hpv vaccine through twitter

Conditions: Human Papilloma Virus

Summary: this study assessed the feasibility of implementing a one-month twitter campaign to promote knowledge about the human papillomavirus (hpv) vaccine among low-income women living in public housing.

investigators recruited a convenience sample (n=35) of women ages 18-26 years who resided in public housing in massachusetts. investigators assessed the feasibility and acceptability of the campaign. online assessed changes in hpv knowledge, attitudes, and vaccine intentions before and after the campaign.

Eligibility criteria:
inclusion criteria: english-speaking women age18-26 years residents of public housing in two massachusetts cities

Keywords: vaccination feasibility public housing
multicenter prospective cohort study on tam receptor tyrosine kinase ligands for predicting the severity of acute pancreatitis

Conditions: Acute Pancreatic Necrosis; Acute Pancreatitis (AP)

Summary: axl and mertk are homologous members of the tam (tyro3, axl, mertk) receptor tyrosine kinase family. they function as critical regulators of antiviral immunity, autoimmune responses, and tumor microenvironment modulation through their bridging ligands, gas6 (growth arrest-specific 6) and pros1 (protein s). these receptors serve as damage sensors that negatively regulate inflammation, promote tissue repair/remodeling, and modulate fibrotic processes in chronic inflammatory conditions. building upon our previous work demonstrating the pivotal role of the axl/mertk signaling axis in ap pathogenesis - particularly in pancreatic necrosis regulation, this clinical study seeks to evaluate the prognostic value of the tam receptor ligands gas6 and pros1 as biomarkers for predicting ap severity.


Eligibility criteria:
inclusion criteria: 1. age 18-80 years. 2. patients diagnosed with acute pancreatitis in outpatient/emergency departments, inpatient wards, or health examination centers starting from 2024. exclusion criteria: 1. patients with chronic pancreatitis or pancreatic cancer. 2. pregnant or lactating women. 3. patients who did not provide informed consent. 4. patients with severe organic diseases, such as malignant tumors, acute myocardial infarction, or large-scale cerebral infarction.
prospective randomized pilot study comparing inferior versus superior conjunctival autografts for primary pterygia

Conditions: Pterygium

Summary: the purpose of this study is to determine if there is any difference in the surgical time when the surgery is performed with a graft taken from under the upper lid versus lower lid. the investigators will also be recording the level of pain felt by patients after surgery, any difficulties during or after surgery, and if the pterygium grows back.


Eligibility criteria:
inclusion criteria: * primary pterygium (no previous surgeries or radiotherapy) requiring excision due to ocular discomfort or disruption in vision * ability to understand the nature of the procedure and to complete all measurement requirements * patients must be eligible for either the superior or inferior conjunctival autografts (they must not meet any of the following exclusion criteria) * adults (age \>18) exclusion criteria: * ocular surface disease apart from pterygium (such as severe dry eye, corneal disease, scarring from previous infection, radiotherapy, inflammatory diseases or trauma) * patients who have had previous ocular surface surgery * patients with glaucoma or those who may need glaucoma surgery in the future * contraindications to local anesthetics (such as known allergy) * pregnancy (as the risk to the fetus with the use of topical antibiotic drops and local anesthetics are not known)
post-traumatic neuropathy of the trigeminal nerve

Conditions: Nerve Injury; Orofacial Pain; Trigeminal Nerve Injuries; Trigeminal Neuropathy

Summary: this is retrospective research mainly aims to determine the patterns of symptoms, clinical and radiological findings and outcomes in patients with trigeminal neuropathy following trauma or iatrogenic damage and how this translates into costs for the patient and society, work disability and medication use. the trigeminal nerve and its branches are at risk of damage during multiple dental and maxillofacial procedures: endodontics, extractions, removal of wisdom teeth, implant placement, use of local anaesthesia, orthognatic surgery. in the event of damage to these nerve branches, there is a high risk of developing a neuropathic pain that is considered very disabling for patients and that interferes with daily activities (eating, drinking, speaking, kissing, etc.). moreover, there are few medicinal or surgical techniques available to eliminate neuropathy or reduce the symptoms. causal procedures (e.g. the removal of wisdom teeth) are among the most frequently performed surgical procedures. the number of injuries increases every year, partly due to an increase in dental procedures. the often relatively minimal intervention combined with the major impact of these injuries on the patient's quality of life sometimes leads to medico-legal actions. the limited symptom control with current therapies of these post-traumatic neuropathies of the trigeminal nerve causes frustration and impotence in both the patient and the attending physician, which can also lead to medical shopping. based on chart analysis, this study will examine the causes, possible risk factors and presenting symptoms, how this is reflected in clinical research and examinations, and which treatments are being instituted. patient records from the oral and maxillofacial surgery department between january 2010 and october 2018 will be checked. in addition, we wish to check the costs incurred by these patients as well as the work disability. to this end, a collaboration is being organised with christian mutuality (cm), the largest health insurance provider in belgium. in order to increase the power of the study, the clinical data from the already coded, retrospective dataset of prof. tara renton, co-investigator, will be transferred to the dataset of this new study.


Eligibility criteria:
inclusion criteria: * presentation with post traumatic, iatrogenic, injury of the trigeminal nerve or its branches (eg. inferior alveolar nerve, lingual nerve) * iatrogenic nerve injury caused by m3 removal, implant placement, orthognathic surgery, endodontic therapy, non-m3 removal, local anesthesia injection, trauma. * clinical diagnosis of neurosensory deficit in the distribution of the trigeminal nerve caused by a previous dental or maxillofacial procedure in the vicinity of the affected branch. exclusion criteria: * neuropathic pain in another region than the trigeminal nerve * neuropathic pain not caused by iatrogenic injury

Keywords: post-traumatic trigeminal neuropathic pain
nomacopan (rva576) in transplant associated thrombotic microangiopathy

Conditions: Thrombotic Microangiopathies

Summary: multicentre study of nomacopan in paediatric haematopoietic stem-cell transplant associated thrombotic microangiopathy

this is an open-label, multi-centre study of two-parts, part a and b, includes 24 weeks of treatment, safety follow up after 30 days. part a: dose algorithm, safety and efficacy part b: safety and efficacy

Eligibility criteria:
inclusion criteria: 1. aged ≥ 0.5 and \< 18 years at the time of diagnosis of tma. 2. undergone allogeneic or autologous hsct. 3. tma diagnosis within a year of their allogeneic or autologous hsct. 4. clinical or histological diagnosis of tma 5. provision of written informed consent. 6. provision of informed assent exclusion criteria: 1. patients weighing less than 5 kg. 2. patients with a positive direct coombs' test. 3. patients who do not receive nomacopan within 21 days of the initial diagnosis of tma. 4. patients having an active systemic or organ system bacterial or fungal infection or progressive severe infection at the time of diagnosis of tma 5. grade 4 acute graft-versus-host disease (gvhd) 6. received eculizumab or any other complement blocker therapy at any time. 7. known hypersensitivity to the active ingredient or excipients if an enrolled patient has a positive adamts13 test (\<10%) returned from their screening assessment, the patient should be withdrawn from the study